Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$22.55 USD
+0.78 (3.58%)
Updated May 24, 2024 04:00 PM ET
After-Market: $22.45 -0.10 (-0.44%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNTH 22.55 +0.78(3.58%)
Will DNTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
Intel upgraded, Texas Instruments initiated: Wall Street's top analyst calls
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics’ DNTH103: A Potential Game-Changer in Autoimmune Disease Treatment
Dianthus initiated with bullish view at H.C. Wainwright, here's why
H.C. Wainwright starts Dianthus as buy, cites lead drug candidate